The supply price of Bharat Biotech's Covid-19 vaccine Covaxin to the central government at Rs 150 per dose is not sustainable in the long run, the vaccine maker said on Tuesday.

The Centre's supplying price is pushing the pricing structure for the private sector upward. Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin, Bharat Biotech said justifying the higher price when compared to other Covid-19 vaccines available for the private sector in India.